{
  "url": "https://openlegislation.uk/eu-regulation-2016-1085/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2016-1085/annex.json",
  "legislation": "eur/2016/1085",
  "legislation_title": "Commission Implementing Regulation (EU) 2016/1085 of 5 July 2016 approving Bacillus amyloliquefaciens strain ISB06 as an existing active substance for use in biocidal products of product-type 3 (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2016-1085",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.\nCommon Name\nIUPAC NameIdentification Numbers\nMinimum degree of purity of the active substance\nDate of approval\nExpiry date of approval\nProduct type\nSpecific conditions\nBacillus amyloliquefaciens strain ISB06\nNot applicable\nNo relevant impurities\n1 January 2018\n31 December 2027\n3\nThe authorisations of biocidal products are subject to the following conditions:\n1.. The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.\n2.. In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2016/1085/annex",
    "retrieved_at": "2026-11-01T14:45:42.512836+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}